McNicholas, Ruairi and Sweeney, Nicola and Fenton, Fiona and Keenan, Eamon (2025) Enhancing naloxone provision in patients with comorbid mental illness and opioid use disorder amidst the rise of nitazenes in Ireland. Irish Journal of Psychological Medicine, Early online, pp. 1-2. https://doi.org/10.1017/ipm.2025.10102.
Letter to the Editor
Existing research shows that approximately 50% of patients with severe mental illness have a comorbid substance use disorder (Drake et al. Reference Drake, Mueser and Brunette2007). Among the most vulnerable of these patients are those with comorbid opioid use disorders. The HSE National Drug Treatment Centre (NDTC) in Dublin city centre is responsible for the care of many of these vulnerable “dual diagnosis” patients and as such finds itself at the forefront of a new challenge – the rise of synthetic opioids.
B Substances > Opioids (opiates) > Opioid product > Naloxone
B Substances > New (novel) psychoactive substances > Synthetic opioids > Benzimidazole, Nitazenes, Brorphine
G Health and disease > Substance use disorder (addiction) > Multiple substance use (Poly-drug /Poly-substance)
G Health and disease > Substance use disorder (addiction) > Drug use disorder
G Health and disease > Substance related disorder > Substance related mental health disorder > Dual diagnosis / comorbidity (mental health)
VA Geographic area > Europe > Ireland
Click here to request a copy of this literature
Repository Staff Only: item control page